Mark E. Saad - 05 Sep 2025 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)

Role
Director
Signature
/s/ Nick Pizzie, Attorney-in-Fact
Issuer symbol
AXSM
Transactions as of
05 Sep 2025
Net transactions value
-$1,059,371
Form type
4
Filing time
05 Sep 2025, 19:43:07 UTC
Previous filing
10 Jun 2025
Next filing
02 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Saad Mark E Director C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK /s/ Nick Pizzie, Attorney-in-Fact 05 Sep 2025 0001295913

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXSM Common Stock Options Exercise $82,143 +9,127 +91% $9.00 19,129 05 Sep 2025 Direct F1, F2
transaction AXSM Common Stock Sale $1,141,514 -9,127 -48% $125.07 10,002 05 Sep 2025 Direct F2, F3, F4
holding AXSM Common Stock 300 05 Sep 2025 See explanation 5 below. F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXSM Stock Option (Right to Buy) Options Exercise $0 -9,127 -100% $0.000000 0 05 Sep 2025 Common Stock 9,127 $9.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within the next two months.
F2 Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed.
F3 Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
F4 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $125.00 and $125.22.
F5 Represents additional shares held indirectly by the Reporting Person prior to September 5, 2025 which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.